HC Wainwright Issues Optimistic Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – HC Wainwright lifted their Q4 2025 earnings per share estimates for Corcept Therapeutics in a note issued to investors on Thursday, February 27th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.73 for the quarter, up from their prior estimate of $0.70. HC Wainwright has a “Buy” rating and a $115.00 price objective on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ FY2029 earnings at $8.52 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million.

A number of other research firms have also commented on CORT. Piper Sandler raised their price target on Corcept Therapeutics from $67.00 to $78.00 and gave the stock an “overweight” rating in a research report on Thursday. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 25th. Finally, Canaccord Genuity Group raised their price target on Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, January 30th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $99.75.

Corcept Therapeutics Price Performance

Shares of CORT opened at $59.85 on Friday. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. Corcept Therapeutics has a 1 year low of $20.84 and a 1 year high of $75.00. The stock has a market cap of $6.27 billion, a P/E ratio of 47.50 and a beta of 0.58. The stock’s 50-day moving average price is $59.60 and its two-hundred day moving average price is $51.16.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CORT. Vanguard Group Inc. boosted its stake in Corcept Therapeutics by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 10,115,624 shares of the biotechnology company’s stock valued at $509,726,000 after purchasing an additional 109,294 shares during the period. Parallel Advisors LLC boosted its stake in Corcept Therapeutics by 0.4% in the 4th quarter. Parallel Advisors LLC now owns 3,829,632 shares of the biotechnology company’s stock valued at $192,975,000 after purchasing an additional 15,908 shares during the period. State Street Corp boosted its stake in Corcept Therapeutics by 0.6% in the 3rd quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company’s stock valued at $162,871,000 after purchasing an additional 19,893 shares during the period. Geode Capital Management LLC boosted its stake in Corcept Therapeutics by 4.4% in the 3rd quarter. Geode Capital Management LLC now owns 2,378,758 shares of the biotechnology company’s stock valued at $110,108,000 after purchasing an additional 99,470 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in Corcept Therapeutics by 4.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,644,942 shares of the biotechnology company’s stock valued at $82,889,000 after purchasing an additional 64,321 shares during the period. 93.61% of the stock is currently owned by institutional investors.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $59.46, for a total value of $130,812.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Sean Maduck sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $50.39, for a total value of $1,007,800.00. Following the completion of the transaction, the insider now owns 85,318 shares of the company’s stock, valued at approximately $4,299,174.02. This represents a 18.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 26,600 shares of company stock valued at $1,399,576. 20.50% of the stock is owned by insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.